Delving into the Latest Updates on Guangzhou Zhiyao Biotechnology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	4

1.评估GBI268单次给药用于开放式单侧拇外翻矫形手术术后镇痛的有效性。 2.探索GBI268单次给药用于开放式单侧拇外翻矫形手术术后镇痛的合理剂量。 3.评价GBI268单次给药用于开放式单侧拇外翻矫形手术术后镇痛的安全性。 4.评价GBI268单次给药用于开放式单侧拇外翻矫形手术术后镇痛的药代动力学（PK）特征。

[Translation]

1. To evaluate the effectiveness of a single administration of GBI268 for postoperative analgesia in open unilateral hallux valgus surgery. 2. To explore the reasonable dose of GBI268 for postoperative analgesia in open unilateral hallux valgus surgery. 3. To evaluate the safety of a single administration of GBI268 for postoperative analgesia in open unilateral hallux valgus surgery. 4. To evaluate the pharmacokinetic (PK) characteristics of a single administration of GBI268 for postoperative analgesia in open unilateral hallux valgus surgery.

Start Date10 Feb 2025

Sponsor / Collaborator

Guangzhou Zhiyao Biotechnology Co., Ltd.

CTR20242473

/ CompletedPhase 1

评价GBI268注射液在中国健康成年受试者中的随机、双盲、阳性药和安慰剂对照、单次给药剂量递增的安全性、耐受性、药代动力学和初步药效学的I 期临床研究

[Translation] A randomized, double-blind, active-drug and placebo-controlled, single-dose escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of GBI268 injection in healthy Chinese adult subjects

1、评估 GBI268 注射液在健康受试者中单次用药后的安全性、耐受性。 2、评估 GBI268 注射液在健康受试者中单次用药后的药代动力学（PK）特征。 3、评估 GBI268 注射液在健康受试者中单次用药后的初步药效学特征。

[Translation]

1. Evaluate the safety and tolerability of GBI268 injection after a single dose in healthy subjects. 2. Evaluate the pharmacokinetic (PK) characteristics of GBI268 injection after a single dose in healthy subjects. 3. Evaluate the preliminary pharmacodynamic characteristics of GBI268 injection after a single dose in healthy subjects.

Start Date23 Jul 2024

Sponsor / Collaborator

Guangzhou Zhiyao Biotechnology Co., Ltd.

100 Clinical Results associated with Guangzhou Zhiyao Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Zhiyao Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Guangzhou Zhiyao Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Zhiyao Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 2

Login to view more data